서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Subject

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 36 of 36

Issue DateTitle / Author(s) / CitationFileAltmetrics
1998-01
Influence of exposure and infusion times on the cytotoxicity and pharmacokinetics of cis-malonato[(4R, 5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II)
DOI
1999-10
Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma
DOI
2001-04
A phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies
DOI
2003-12
Synthesis and Biological Evaluation of 3-(4-Substituted-phenyl)-N-hydroxy-2-propenamides, a New Class of Histone Deacetylase Inhibitors
DOI
2004-01
Activation of protein kinase C by 1-β-D-arabinofuranosylcytosine conjugates of phospholipid

Lee, KH; Jung, YJ; Hong, CI; Cho, MH; Bai, DH; Kim, SH; Choi, KY; Yu, JH; Kim, CM

International Journal of Oncology, Vol.24 No.1, pp.193-199

DOI
2004-08
Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation
DOI
2008-01
Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin
DOI
2008-03
Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells

Kim, Hwang-Phill; Han, Sae-Won; Kim, Sung-Hak; Im, Seock-Ah; Oh, Do-Youn; Bang, Yung-Jue; Kim, Tae-You

Molecular Cancer Therapeutics, Vol.7 No.3, pp.607-615

DOI
2008-06
Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer
DOI
2008-12
The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines
DOI
2011-02
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
DOI
2011-07
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma
DOI
2011-12
Phase II study of sunitinib as second-line treatment for advanced gastric cancer
DOI
2012-03
Synergistic effects of Akt1 shRNA and paclitaxel-incorporated conjugated linoleic acid-coupled poloxamer thermosensitive hydrogel on breast cancer
DOI
2012-04
NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations

Park, Eunju; Park, Jinah; Han, Sae-Won; Im, Seock-Ah; Kim, Tae-You; Oh, Do-Youn; Bang, Yung-Jue

International Journal of Oncology, Vol.40 No.4, pp.1259-1266

DOI
2013-09
Thymoquinone inhibits phorbol ester-induced activation of NF-kappa B and expression of COX-2, and induces expression of cytoprotective enzymes in mouse skin in vivo

Kundu, Joydeb Kumar; Liu, Lijia; Shin, Jun-Wan; Surh, Young-Joon

Biochemical and Biophysical Research Communications, Vol.438 No.4, pp.721-727

DOI
2014-04
Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signaling

Lee, Jin-Ku; Joo, Kyeung Min; Lee, Jeongwu; Yoon, Yeup; Nam, Do-Hyun

OncoTargets and Therapy, Vol.7, pp.1933-1944

DOI
2016-01
Phase I study of CKD-516, a novel vascular disrupting agent, in patients with advanced solid tumors
DOI
2016-03
A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806)
DOI
2016-07
Src as a Therapeutic Target in Biliary Tract Cancer
DOI
2017-01
Inhibition of allergic response by intranasal selective NF-κB decoy oligodeoxynucleotides in a murine model of allergic rhinitis

Wee, Jee Hye; Zhang, Yu-Lan; Rhee, Chae-Seo; Kim, Dong-Young

Allergy, Asthma & Immunology Research, Vol.9 No.1, pp.61-69

DOI
2017-02
Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study
DOI
2017-08
Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer
DOI
2017-10
A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors
DOI
2018
15-Deoxy-Delta(12,14)-prostaglandin J(2) activates PI3K-Akt signaling in human breast cancer cells through covalent modification of the tumor suppressor PTEN at cysteine 136
DOI
2018-07
Phase 1 studies of poziotinib, an irreversible pan-her tyrosine kinase inhibitor in patients with advanced solid tumors
DOI
2018-12
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial
DOI
2019-02
The role of p53 status on the synergistic effect of CKD-602 and cisplatin on oral squamous cell carcinoma cell lines

Choi, Hyeong Sim; Kim, Young Kyun; Yun, Pil Young

Molecular Biology Reports, Vol.46 No.1, pp.617-625

DOI
2019-02
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
DOI
2019-06
Challenges and insights of early oncology drug development in the Asia-Pacific region: introduction of phase I oncology clinical trial center and experience sharing for early clinical trials in Seoul National University Hospital, Korea
view fileDOI
2019-07
Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018
DOI
2020-01
HER2-targeted therapies - a role beyond breast cancer

Oh, Do-Youn; Bang, Yung-Jue

Nature Reviews Clinical Oncology, Vol.17 No.1, pp.33-48

DOI
2020-04
Involvement of ER stress and reactive oxygen species generation in anti-cancer effect of CKD-516 for lung cancer

Kim, Soo Jin; Jegal, Kyung Hwan; Im, Ji-Hye; Park, Gyutae; Kim, Suntae; Jeong, Hye Gwang; Cho, Il Je; Kang, Keon Wook

Cancer Chemotherapy and Pharmacology, Vol.85 No.4, pp.685-697

DOI
2020-11
Preparation and characterization of sorafenib-loaded microprecipitated bulk powder for enhancing oral bioavailability

Park, Ju-Hwan; Baek, Min-Jun; Lee, Jae-Young; Kim, Ki-Taek; Cho, Hyun-Jong; Kim, Dae-Duk

International Journal of Pharmaceutics, Vol.589, p. 119836

DOI
2021-07
Pharmacokinetic aspects of the clinically used proteasome inhibitor drugs and efforts toward nanoparticulate delivery systems

Kwon, Seungbin; Kim, Kyung Bo; Yeo, Yoon; Lee, Wooin

Journal of Pharmaceutical Investigation, Vol.51 No.4, pp.483-502

DOI
2021-12
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors
DOI
1